Since 2017, immune checkpoint inhibitors, such as nivolumab, pembrolizumab, camrelizumab and atezolizumab, which are PD-1/PDL-1 and CTLA-4 inhibitors, have been widely applied to treat hepatocellular carcinoma. Here, CTLA4 is linked to hepatocellular carcinoma.